T1	Participants 14 149	Cobicistat Compared With Ritonavir as a Pharmacoenhancer for Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate
T2	Participants 151 167	Week 144 Results
T3	Participants 181 253	Cobicistat (COBI) is a pharmacoenhancer with no antiretroviral activity.
T4	Participants 262 387	International, randomized double-blind active-controlled trial to evaluate the efficacy and safety of COBI vs ritonavir (RTV)
T5	Participants 393 519	pharmacoenhancer of atazanavir in combination with emtricitabine/tenofovir disoproxil fumarate in HIV treatment-naive patients
T6	Participants 568 642	virologic suppression was achieved in 72% (COBI) and 74% (RTV) of patients
T7	Participants 862 956	Once-daily COBI is a safe and effective pharmacoenhancer of the protease inhibitor atazanavir.
